相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma
Maria C. Schwaederle et al.
CLINICAL CANCER RESEARCH (2017)
Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary
Shumei Kato et al.
CANCER RESEARCH (2017)
The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?
Dorota Kwapisz
ANNALS OF TRANSLATIONAL MEDICINE (2017)
Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients
Maria Schwaederle et al.
CLINICAL CANCER RESEARCH (2016)
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1
Matthew Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J. Chabon et al.
NATURE COMMUNICATIONS (2016)
Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
Maria Schwaederle et al.
ONCOTARGET (2016)
MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors
Denis L. F. Jardim et al.
CLINICAL GENITOURINARY CANCER (2015)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
Juan Madoz-Gurpide et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
Richard B. Lanman et al.
PLOS ONE (2015)
Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis
Shoichiro Mukai et al.
HUMAN CELL (2015)
Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit
Debora de Melo Gagliato et al.
CLINICAL BREAST CANCER (2014)
Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic
Denis L. F. Jardim et al.
CLINICAL CANCER RESEARCH (2014)
Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy
Rana R. Mckay et al.
EUROPEAN UROLOGY (2014)
Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma
Francois-Clement Bidard et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib
Timothy J. Graham et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Targeting MET Amplification as a New Oncogenic Driver
Hisato Kawakami et al.
CANCERS (2014)
MET Gain in Diffuse Astrocytomas is Associated with Poorer Outcome
Daniela Pierscianek et al.
BRAIN PATHOLOGY (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
分享论文
